Clinical trials: Rejection
Kidney Transplant Rejection, Immunosuppression
Immunosuppression Management in Renal Transplant Recipients With Transplant Excellence Based on TruGraf Test
This is an investigator-initiated, single-center, prospective, randomized, proof of concept study. In this study patients who are status post kidney transplantation and meet the inclusion and exclusion criteria will undergo…
- Trial name
- NCT04670926
- Testing
- TruGraf, Standard of Care
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Transplant Genomics, Inc.
Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation
Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation
Advances in renal transplantation have increased life-expectancy in patients with end-stage kidney disease. Conventional immunosuppressive drugs prevent efficiently early allograft losses due to T-cell mediated rejection.
- Trial name
- TAMARCIN (NCT02113891)
- Testing
- Eculizumab
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pancreas Transplant Rejection, Kidney Transplant Rejection
Donor-Derived Cell-Free DNA for Surveillance in Simultaneous Pancreas and Kidney Transplant Recipients
The AlloSure test is approved by the Centers for Medicare \& Medicaid Services (CMS) for use in Medicare patients to assess the probability of allograft rejection in kidney transplant patients.
- Trial name
- NCT04130685
- Testing
- Allosure Test
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Rush University Medical Center
Renal Transplant Rejection
Simulect Versus ATG in Sensitized Renal Transplant Patient
Induction therapy by either T-cell depleting polyclonal antibodies such as anti-thymocyte globulins (ATG) or non-depleting anti-interleukine 2 receptor monoclonal antibodies (anti-CD25 moAb: basiliximab or daclizumab) are used to…
- Trial name
- SATIR (NCT02377193)
- Testing
- Simulect, ATG Fresenius
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Toulouse
Graft Rejection, Lung Disease
Lung Allograft Rejection Gene Expression Observational (LARGO) Study
The objective of the LARGO Study protocol is to collect peripheral blood samples, select associated lung biopsy pathology slides, and clinical data from lung transplant recipients to perform molecular analyses in association with…
- Trial name
- LARGO (NCT00751309)
- Testing
- Non-interventional
- Where
- 20 sites in United States, Austria and 3 more
- Volunteers
- 2,044 people, healthy volunteers welcome
- Sponsor
- XDx
Acute Rejection, Renal Transplantation
Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation
The hypothesis of this study is that lymphocyte depletion by Campath-1H and rituximab will obviate the need for long-term calcineurin inhibitors in renal transplantation.
- Trial name
- NCT00579592
- Testing
- Campath-1H, rituximab, myfortic
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Wisconsin, Madison
Kidney Transplant; Complications, Immunosuppression
Efficacy of Single Dose Anti-thymocyte Globulin in the Modulation of T Lymphocytes in Kidney Transplantation
The use of polyclonal anti-T cell antibodies (ATG) has benefits in kidney transplantation, however, its use is associated mainly with hematological, infectious, and neoplastic complications.
- Trial name
- NCT04835948
- Testing
- single dose of Anti-thymocyte globulin
- Where
- Brazil
- Volunteers
- 200 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Acute Cellular Graft Rejection, Cardiac Sarcoidosis
[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation
Acute myocardial inflammation is an heterogenic syndrome involving different clinical pathologies with different outcome. For the purpose of this study protocol, we focuse on three entities of this syndrome, namely the acute…
- Conditions
- Acute Cellular Graft Rejection, Cardiac Sarcoidosis, Myocarditis Due to Drug
- Trial name
- NCT05499637
- Testing
- [68Ga]Ga-PentixaFor PET/CT
- Where
- Switzerland
- Volunteers
- 25 people
- Sponsor
- John O. Prior
Kidney Diseases, Kidney Injury
ID-ENTITY Trial- Evaluating Serial T-ID Monitoring
To evaluate the association between time-updated CMV and BK viral loads measured monthly by T-ID and the risk of CMV disease and/or biopsy-proven BK virus-associated nephropathy (BKVAN) during the first 12 months following kidney…
- Conditions
- Kidney Diseases, Kidney Injury, BK Virus Infection, CMV
- Trial name
- ID-ENTITY (NCT07393594)
- Testing
- Blood tests, TRAC( cell free DNA) and T-ID
- Where
- 14 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Transplant Genomics, Inc.
Kidney Transplant Failure and Rejection
Prospective Assessment of Rejection in Kidney Transplant (PARK)
The PARK study is a multi-center observational study to assess the performance of the QSant test with kidney biopsy. QSant is a test based on 6 urinary biomarkers that is used for the evaluation and management of acute rejection…
- Trial name
- PARK (NCT05715853)
- Testing
- QSant
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- NephroSant
Liver Transplant; Complications, Transplant; Failure, Liver
Liver Transplantation After ex Vivo Liver Perfusion
Today, it is difficult to predict liver function after transplantation and therefore livers where poor function is assumed (marginal livers) become discarded.
- Conditions
- Liver Transplant; Complications, Transplant; Failure, Liver, Transplant Dysfunction, Transplant; Complication, Rejection
- Trial name
- EVOLVE (NCT05951231)
- Testing
- Liver transplantation
- Volunteers
- 22 people
- Sponsor
- Oslo University Hospital
Heart-lung Transplant Rejection
Assessment of Revascularization Versus Conservative Treatment in Heart Transplant Patients for a Clinical Event Reduction
The aim of the study is to compare optimal medical therapy alone versus percutaneous coronary intervention on top of medical therapy in the setting of heart transplant recipient coronary artery disease in a randomized trial.The…
- Trial name
- ARCHER (NCT01795729)
- Testing
- Stent, optimal medical therapy
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Kidney Transplant Rejection
An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients
The purpose of this study was to investigate how efficiently the study medication imlifidase reduces the amount of donor specific antibodies (DSA) in comparison with plasma exchange (PE) therapy, in patients who have had an…
- Trial name
- NCT03897205
- Testing
- Imlifidase, Plasma Exchange
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 30 people
- Sponsor
- Hansa Biopharma AB
Kidney Transplantation, Acute Rejection of Renal Transplant
Donor-derived Cell-free DNA in Kidney Transplant Recipients
Donor-derived cell-free DNA (dd-cfDNA) is a promising non-invasive biomarker of kidney allograft rejection. In this prospective, single center, observational monitoring study, we aim to evaluate a role of dd-cfDNA in predicting…
- Trial name
- DEFILE (NCT06476717)
- Testing
- Biopsy, Blood Biomarkers - cfDNA, Antirejection therapy
- Where
- Czechia
- Volunteers
- 143 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Renal Transplant Rejection
Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids
The main objective of the study is the assessment of the overall graft rejection rate (acute, chronic and subclinical) between a treatment with ATG-Fresenius administered in addition to standard treatment consisting of CellCept®…
- Trial name
- IBERICA (NCT01324934)
- Testing
- ATG-Fresenius S
- Where
- 10 sites in Portugal, Spain
- Volunteers
- 40 people
- Sponsor
- Neovii Biotech
Kidney Transplant Failure and Rejection
A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression
This is an open label, single-center, randomized phase IV pilot study of steroid and calcineurin inhibitor avoidance in renal transplant recipients.
- Trial name
- Cell220 (NCT00166712)
- Testing
- Tacrolimus (TAC), Sirolimus, Alemtuzumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Northwestern University
Graft Rejection, Kidney Transplantation
A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure
A study to compare the conversion to Prograf® (tacrolimus) to the continuation of cyclosporine in patients at risk for chronic renal allograft failure
- Trial name
- CRAF (NCT00510913)
- Testing
- tacrolimus
- Where
- 18 sites in United States
- Volunteers
- 450 people
- Sponsor
- Astellas Pharma Inc
Graft Rejection, Kidney Failure
Study Comparing Two Sirolimus Regimens vs. Tacrolimus and Mycophenolate Mofetil Regimen in Kidney Transplant Recipients
To demonstrate the superiority of SRL + TAC elimination + corticosteroids (Group I) and SRL + MMF + corticosteroids (Group II) to TAC + MMF + corticosteroids (Group III) with respect to renal allograft function at month 12…
- Conditions
- Graft Rejection, Kidney Failure, Kidney Transplant
- Trial name
- NCT00266123
- Testing
- Sirolimus
- Volunteers
- 420 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Rejection Sensitivity, Puberty
Rejection Sensitivity and Puberty in Mental Health Vulnerability to Social Media Experiences in Early Adolescent Girls
This longitudinal study is designed to test bidirectional relationships between preteen girls' mental health and social media experiences.
- Conditions
- Rejection Sensitivity, Puberty, Psychopathology
- Trial name
- NCT06777823
- Testing
- Social Rejection Task
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Heart Transplant Failure and Rejection
A Clinical Study of Association Between Postoperative Dyslipidemia and Organ Rejection in Transplant Patients
Abnormal lipid metabolism is a common complication after organ transplantation, with pathological changes in lipid parameters occurring in approximately 60-80% of cardiac transplant recipients receiving triple immunotherapy with…
- Trial name
- NCT05994274
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology